Association between human leukocyte antigen class I and II alleles and hepatitis C virus infection in high-risk hemodialysis patients awaiting kidney transplantation

详细信息    查看全文

• 作者：Vincenzo Grimaldi ; Linda Sommese ; Antonietta Picascia ; Amelia Casamassimi ; Francesco Cacciatore ; Andrea Renda ; Paride De Rosa ; Maria Lourdes Montesano ; Chiara Sabia ; Carmela Fiorito ; Gustavo De Iorio ; Claudio Napoli
• 关键词：HCV ; hepatitis C virus ; OR ; odds ratios ; CI ; confidence intervals ; NK ; natural killer ; CMIA ; chemiluminescent microparticle immunoassay ; RIBA ; recombinant immunoblot assay ; SPSS ; statistical package of social science
• 刊名：Human Immunology
• 出版年：December, 2013
• 年：2013
• 卷：74
• 期：12
• 页码：1629-1632
• 全文大小：361 K

文摘

Recent evidences have shown that several host genetic factors influence susceptibility or protection to hepatitis C virus (HCV) infection. There are controversial data regarding the associations of human leukocyte antigens (HLA) and the clearance or progression of HCV. The aim of this study was to investigate whether particular HLA molecules were associated with HCV infection in recipients awaiting kidney transplantation considered at high-risk to infection due to protracted hemodialysis treatment. To this purpose, 301 kidney recipients with HCV infection and 1103 uninfected recipients were examined for HLA class I and II molecules. In our case-control study, HLA-A^*26 is positively associated with HCV infection while HLA-A^*29, -B^*40 and -DRB1^*01 are negatively associated with HCV infection. Multiple logistic regression analysis demonstrated that age (OR = 1.02; 95% CI = 1.01-1.04; p < 0.00), HLA-A^*26, -A^*29, -B^*40 and -DRB1^*01 [(OR = 1.54; 95% CI = 1.03-2.30; p = 0.03); (OR = 0.50; 95% CI = 0.26-0.99; p = 0.05); (OR = 0.42; 95% CI = 0.23-0, 7; p = 0.01); (OR = 0.62; 95% CI = 0.41-0, 94; p = 0.03); respectively] are independent predictors of HCV infection. Our results suggest that particular HLA molecules, as host genetic factors, may have a relationship with susceptibility or protection to HCV infection also in recipients awaiting kidney transplantation.